Clinically, its prognostic relevance has been validated across multiple cancers: elevated TPD52L2 independently predicts biochemical recurrence in prostate cancer [51], is correlated with poor survival and immune dysregulation in renal clear cell carcinoma [52], and drives glioma progression through bypass of G0/G1 arrest [26, 53]. This evidence concerns the gene TPD52L2 and prostate carcinoma.